The cost-utility of targeted germline BRCA testing in localized prostate cancer followed by cascade testing first-degree relatives with pathogenic variants.

doi:10.1016/j.gim.2025.101463

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The cost-utility of targeted germline BRCA testing in localized prostate cancer followed by cascade testing first-degree relatives with pathogenic variants.

Genetics in medicine : official journal of the American College of Medical Genetics - 1 Aug 2025

Teppala Srinivas, Scuffham Paul, Edmunds Kim, Roberts Matthew J, Smith David P, Fairbairn David, Horvath Lisa G, Tuffaha Haitham

Abstract excerpt

PURPOSE: Genetic testing is recommended in localized prostate cancer (PCa) with elevated risk and in metastatic PCa. The economics of genetic testing in metastatic PCa has been evaluated but not assessed in localized PCa. We examined the cost utility of germline BRCA testing in localized PCa with high risk of pathogenic variants. METHODS: Cost-utility analysis of germline BRCA testing in localized PCa with (1)...

Read the complete abstract on PubMed

Topics

Humans
Male
Prostatic Neoplasms
Genetic Testing
Cost-Benefit Analysis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Germ-Line Mutation

BRCA2 Protein

Genetic Predisposition to Disease

BRCA1 Protein

Quality-Adjusted Life Years

Australia

Middle Aged

Aged

Source

Open in PubMed

Identifiers

PMID: 40417742
DOI: 10.1016/j.gim.2025.101463

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The cost-utility of targeted germline BRCA testing in localized prostate cancer followed by cascade testing first-degree relatives with pathogenic variants.PMID 40417742Read ↗

The Cost-Effectiveness of Germline BReast CAncer Gene Testing in Metastatic Prostate Cancer Followed by Cascade Testing of First-Degree Relatives of Mutation Carriers.Semantic proximity Read ↗

Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers.Semantic proximity Read ↗

Expected costs and benefits of genetic counselling and germline genetic testing in metastatic prostate cancer.Semantic proximity Read ↗

Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.Semantic proximity Read ↗

The cost-effectiveness of germline BRCA testing-guided olaparib treatment in metastatic castration resistant prostate cancerSemantic proximity Read ↗

Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms.Semantic proximity Read ↗

Preventing future cancers by testing women with ovarian cancer for BRCA mutations.Semantic proximity Read ↗

Cost-effectiveness of testing for breast cancer susceptibility genes.Semantic proximity Read ↗

Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations.Semantic proximity Read ↗

A cost-effectiveness model of genetic testing and periodical clinical screening for the evaluation of families with dilated cardiomyopathySemantic proximity Read ↗

Polygenic susceptibility to prostate and breast cancer: implications for personalised screening.Semantic proximity Read ↗

Estimating the survival benefits gained from providing national cancer genetic services to women with a family history of breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.